|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Prazosin#Warnings]] |
| {{Prazosin}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==PRECAUTIONS==
| |
| | |
| ===General===
| |
| | |
| Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative [[miosis]] despite preoperative dilation with standard [[mydriatic]] drugs, and potential prolapse of the iris toward the [[phacoemulsification]] incisions. The patient's ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or [[viscoelastic]] substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to [[cataract]] surgery.
| |
| | |
| ===Information for Patients===
| |
| | |
| [[Dizziness]] or [[drowsiness]] may occur after the first dose of this medicine. Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased. Dizziness, [[lightheadedness]], or [[fainting]] may occur, especially when rising from a lying or sitting position. Getting up slowly may help lessen the problem. These effects may also occur if you drink alcohol, stand for long periods of time, exercise, or if the weather is hot. While taking MINIPRESS, be careful in the amount of alcohol you drink. Also, use extra care during exercise or hot weather, or if standing for long periods. Check with your physician if you have any questions.
| |
| | |
| ===Drug Interactions===
| |
| | |
| MINIPRESS has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) [[cardiac glycosides]]–[[digitalis]] and [[digoxin]]; (2) hypoglycemics–[[insulin]], [[chlorpropamide]], [[phenformin]], [[tolazamide]], and [[tolbutamide]]; (3) [[tranquilizers]] and sedatives–[[chlordiazepoxide]], [[diazepam]], and [[phenobarbital]]; (4) antigout–[[allopurinol]], [[colchicine]], and [[probenecid]]; (5) [[antiarrhythmics]]–[[procainamide]], [[propranolol]] (see WARNINGS however), and [[quinidine]]; and (6) [[analgesics]], [[antipyretics]] and anti-inflammatories–[[propoxyphene]], [[aspirin]], [[indomethacin]], and [[phenylbutazone]].
| |
| | |
| Addition of a [[diuretic]] or other [[antihypertensive]] agent to MINIPRESS has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the MINIPRESS dose to 1 to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating MINIPRESS based on clinical response.
| |
| | |
| Concomitant administration of MINIPRESS with a [[phosphodiesterase]]-5 ([[PDE-5]]) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see DOSAGE AND ADMINISTRATION).
| |
| | |
| ===Drug/Laboratory Test Interactions===
| |
| | |
| In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of [[norepinephrine]] and an average increase in urinary VMA of 17%. Therefore, false positive results may occur in screening tests for [[pheochromocytoma]] in patients who are being treated with prazosin. If an elevated [[VMA]] is found, prazosin should be discontinued and the patient retested after a month.
| |
| | |
| ===Laboratory Tests===
| |
| | |
| In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre- and post-treatment lipid levels.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MINIPRESS (PRAZOSIN HYDROCHLORIDE) CAPSULE [PFIZER LABORATORIES DIV PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=36c4da56-502e-4da1-acf7-8e81ee453dcc | publisher = | date = | accessdate = 6 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |